Compositions and methods utilizing DNA polymerases

• US 8,268,605 B2
• Filed: 06/29/2001
• Issued: 09/18/2012
• Est. Priority Date: 10/29/1999
• Status: Expired due to Term

• Current Assignee: Agilent Technologies, Inc.
• Original Assignee: Agilent Technologies, Inc.
• Inventors: Sorge, Joseph A., Hansen, Connie Jo, Hogrefe, Holly
• Primary Examiner(s): Hutson, Richard
• Application Number:
  US09/896,923
• Publication Number:
  US 20030157483A1
• Time in Patent Office: 4,099 Days
• Field of Search: 435/194, 435/183, 435/91.2, 530/350, 530/23.2
• US Class Current: 435/194
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12N 9/1252 DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
• CPC Class Codes: C12N 9/1276 RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase

Abstract

The invention features a novel isolated Family B DNA polymerase, a Thermococcus polymerase JDF-3, and mutant recombinant forms thereof. Mutant polymerases of the invention are deficient in 3′ to 5′ exonuclease activity and/or exhibit reduced discrimination against non-conventional nucleotides relative to the wild-type form of the polymerase.

Claims

1. A composition for identifying a nucleotide at a given position of a template DNA molecule, said composition comprising:

a Family B DNA polymerase deficient in 3′

to 5′

exonuclease activity comprising the amino acid sequence of one of SEQ ID NOs;

2 and 62-78, except

a first mutation at amino acid D or E or both in the exo I (DXE) motif within said SEQ ID NO, and

a second mutation at an amino acid selected from the group consisting of;

amino acid L, P, and both L and P in Region II (DXXSLYPSII, SEQ ID NO;

7) within said SEQ ID NO, wherein said second mutation confers a reduction in discrimination.

2. The composition of claim 1, wherein said mutations are selected from the group consisting of:

D141A or D141T, E143A, L408H or L408F, and P410L.

3. The composition of claim 2, wherein said mutations are D141A, E143A, and P410L.

4. The composition of claim 1, further comprising a first primer.

5. The composition of claim 4, further comprising at least one chain-terminating nucleotide analog, wherein said chain-terminating nucleotide analog is incorporated into said first primer by said Family B DNA polymerase in a template-dependent manner.

6. The composition of claim 5, wherein at least one chain-terminating nucleotide analog is labeled with a first detectable label.

7. The composition of claim 5, wherein more than one chain-terminating nucleotide analog is labeled, each chain-terminating nucleotide analog being labeled with a different first delectable label.

8. The composition of claim 5, wherein said chain-terminating nucleotide analog is a dideoxynucleotide.

9. The composition of claim 8, wherein said dideoxynucleotide is selected from the group consisting of:

ddATP, ddTTP, ddCTP and ddGTP.

10. The composition of claim 6, wherein said first primer is labeled with a second detectable label.

11. The composition of claim 10, wherein first and second detectable labels generate a signal for identifying said nucleotide at the given position of the template DNA molecule.

12. The composition of claim 4, further comprising a second primer, wherein said first primer is labeled with a first detectable label and said second primer is labeled with a second detectable label, said first and second detectable labels generate a signal for identifying said nucleotide at the given position of the template DNA molecule.

13. The composition of claim 12, wherein said second primer anneals to the immediate 5′

of said nucleotide at the given position of said template DNA molecule.

14. The composition of claim 13, further comprising a DNA ligase.

15. The composition of claim 1, further comprising a reaction buffer for said Family B DNA polymerase.

16. The composition of claim 1, wherein said template DNA molecule is the product of a polymerase chain reaction or a plasmid DNA.

17. The composition of claim 6, 10, or 12, wherein said first or second detectable label is one selected from the group consisting of:

a fluorescent label, an isotope, a chemiluminescent label, a quantum dot label, an antigen, or an affinity moiety.

18. The composition of claim 17, wherein said first detectable label is a rhodamine label or a cyanine label.

95. The composition of claim 1, wherein said DNA polymerase has reduced discrimination against a non-conventional nucleotide selected from the group consisting of:

dideoxynucleotides, ribonucleotides and conjugated nucleotides.

19. A kit for identifying a nucleotide at a given position of a template DNA molecule, said kit comprising:

a Family B DNA polymerase deficient in 3′

to 5′

exonuclease activity comprising the amino acid sequence of one of SEQ ID NOs;

2 and 62-78, except

a first mutation at amino acid D or E or both in the exo I (DXE) motif within said SEQ ID NO, and

a second mutation at an amino acid selected from the group consisting of;

amino acid L, P, and both L and P in Region II (DXXSLYPSII, SEQ ID NO;

7) within said SEQ ID NO wherein said second mutation confers a reduction in discrimination.

20. The kit of claim 19, wherein said mutations are selected from the group consisting of:

D141A or D141T, E143A, L408H or L408F, and P410L.

21. The kit of claim 20, wherein said mutations are D141A, E143A, and P410L.

22. The kit of claim 19, wherein said Family B DNA polymerase has reduced discrimination against a non-conventional nucleotide selected from the group consisting of:

dideoxynucleotides, ribonucleotides and conjugated nucleotides.

23. The kit of claim 19, further comprising at least one chain-terminating nucleotide analog, wherein said chain-terminating analog is incorporated into said first primer by said DNA polymerase in a template-dependent manner.

24. The kit of claim 23, wherein said at least one chain-terminating nucleotide analog is labeled with a first detectable label.

25. The kit of claim 23, wherein more than one chain-terminating nucleotide analog is labeled, each chain-terminating nucleotide analog being labeled with a different first detectable label.

26. The kit of claim 23, wherein said chain-terminating nucleotide analog is a dideoxynucleotide.

27. The kit of claim 26, wherein said dideoxynucleotide is selected from the group consisting of:

ddATP, ddTTP, ddCTP and ddGTP.

28. The kit of claim 24, further comprising a first primer, wherein said first primer is labeled with a second detectable label.

29. The kit of claim 28, wherein first and second detectable labels generate a signal for identifying said nucleotide at the given position of the template DNA molecule.

30. The kit of claim 19, further comprising a first and a second primer.

31. The kit of claim 30, wherein said first primer is labeled with a first detectable label and said second primer is labeled with a second detectable label, said first and second detectable labels generate a signal for identifying said nucleotide at the given position of the template DNA molecule.

32. The kit of claim 31, wherein said second primer anneals to the immediate 5′

of said nucleotide at the given position of said template DNA molecule.

33. The kit of claim 32, further comprising a DNA ligase.

34. The kit of claim 19, further comprising a reaction buffer for said Family B DNA polymerase.

35. The kit of claim 19, wherein said template DNA molecule is the product of a polymerase chain reaction or a plasmid DNA.

36. The kit of claim 28, or 31, wherein said first or second detectable label is one selected from the group consisting of:

a fluorescent label, an isotope, a chemiluminescent label, a quantum dot label, an antigen, and an affinity moiety.

37. The kit of claim 36, wherein said first detectable label is a rhodamine label or a cyanine label.

38. The kit of claim 19, 23 or 34, further comprising a control template and/or at least one control primer.

39. The kit of claim 38, comprising a control template and four control primers.

40. A method for identifying a nucleotide at a given position of a template DNA molecule in a sample, said method comprising:

contacting a first primer with said template DNA molecule, wherein said contacting allows said first primer to anneal to the immediate 3′

of said nucleotide at the given position of said template DNA molecule, so as to form a duplex between said first primer and said template DNA molecule;

incubating said duplex in the presence of at least one chain-terminating nucleotide analog and a Family B DNA polymerase deficient in 3′

to 5′

exonuclease activity, said Family B DNA polymerase comprising the amino acid sequence of one of SEQ ID NOs;

2 and 62-78, except

a first mutation at amino acid D or E or both in the exo I (DXE) motif within said SEQ ID NO, and

a second mutation at an amino acid selected from the group consisting of;

amino acid L, P, and both L and P in Region II (DXXSLYPSII, SEQ ID NO;

7) within said SEQ ID NO, wherein said second mutation confers a reduction in discrimination,

wherein said at least one chain-terminating nucleotide analog is labeled with a first detectable label,

wherein said incubating allows the incorporation of a labeled chain-terminating nucleotide analog into said first primer by said DNA polymerase in a template-dependent manner; and

determining the presence or identity of said duplex by a signal generated from said first detectable label as a result of said incubating.

41. The method of claim 40, wherein said mutations are selected from the group consisting of:

D141A or D141T, E143A, L408H or L408F, and P410L.

42. The method of claim 41, wherein said one or more amino acid mutations are D141A, E143A, and P410L.

43. The method of claim 40, wherein more than one chain-terminating nucleotide analog is labeled, each chain-terminating nucleotide analog being labeled with a different first detectable label.

44. The method of claim 40, wherein said chain-terminating nucleotide analog is a dideoxynucleotide.

45. The method of claim 44, wherein said dideoxynucleotide is selected from the group consisting of:

ddATP, ddTTP, ddCTP and ddGTP.

46. The method of claim 40, wherein said first primer is labeled with a second detectable label.

47. The method of claim 46, wherein the first and second detectable labels generate a signal for identifying said nucleotide at the given position of the template DNA molecule.

48. The method of claim 40, wherein said template DNA molecule is the product of a polymerase chain reaction or a plasmid.

49. The method of claim 48, further comprising removing PCR primers and dNTPs from the PCR product before said contacting a first primer with said template DNA molecule.

50. The method of claim 46, wherein said first or second detectable label is one selected from the group consisting of:

a radiolabel, a fluorescent label, a chemiluminescent label, a colorimetric label and an enzymatic label.

51. The method of claim 50, wherein said first detectable label is a rhodamine label or a cyanine label.

52. A DNA polymerase comprising the sequence of SEQ ID NO:

2 except an amino acid mutation at P410 and A485.

53. The DNA polymerase of claim 52, wherein said mutation at position P410 is a P410L mutation.

54. The DNA polymerase of claim 52, wherein said mutation at position A485 is an A485T mutation.

55. The DNA polymerase of claim 52, wherein said mutation at position P410 is a P410L mutation and said mutation at position A485 is a A485T mutation.

56. A DNA polymerase comprising the sequence of SEQ ID NO:

2 except amino acid mutations at

     1) P410 and A485; and

     2) D141, E143, or both.

57. The DNA polymerase of claim 56, wherein the amino acid mutation at D141 is a D141A mutation and the mutation at E143 is a E143A mutation.

58. A composition comprising a DNA polymerase comprising the sequence of SEQ ID NO:

2 except mutations at P410 and A485.

59. The composition of claim 58, wherein said mutation at position P410 is a P410L mutation.

60. The composition of claim 58, wherein said mutation at position A485 is an A485T mutation.

61. The composition of claim 58, wherein said mutation at position P410 is a P410L mutation and said mutation at position A485 is an A485T mutation.

63. The composition of claim 58, further comprising a first primer and at least one chain-terminating nucleotide analog.

64. The composition of claim 63, further comprising two, three, or four chain-terminating nucleotide analogs.

65. The composition of claim 64, wherein at least one said chain-terminating nucleotide analog is labeled with a first detectable label.

66. The composition of claim 65, wherein said first primer is labeled with a second detectable label.

67. The composition of claim 66, wherein said first or second detectable label is one selected from the group consisting of:

a fluorescent label, an isotope, a chemiluminescent label, a quantum dot label, an antigen, and an affinity moiety.

68. The composition of claim 67, wherein said detectable label is a rhodamine label or a cyanine label.

62. A DNA polymerase comprising the sequence of SEQ ID NO:

2 except a P410L mutation, an A485T mutation, a D141A mutation, and a E143 mutation.

69. A kit comprising

a DNA polymerase comprising the sequence of SEQ ID NO:

2 except mutations at positions P410 and A485 and optionally at D141 and E143, and

packaging material therefor.

70. The kit of claim 69, wherein said mutation at position P410 is a P410L mutation.

71. The kit of claim 69, wherein said mutation at position A485 is an A485T mutation.

72. The kit of claim 69, wherein said mutation at position P410 is a P410L mutation and said mutation at position A485 is an A485T mutation.

73. The kit of claim 69, wherein said mutations are P410L, A485T, D141A, and E143A.

74. The kit of claim 73, further comprising a first primer which anneals to a template DNA.

75. The kit of claim 74, further comprising at least one chain-terminating nucleotide analog, wherein said chain-terminating nucleotide analog is incorporatable into said first primer by said DNA polymerase in a template-dependent manner.

76. The kit of claim 75, further comprising two, three, or four chain-terminating nucleotide analogs.

77. The kit of claim 75, wherein said at least one said chain-terminating nucleotide analog is labeled with a first detectable label.

78. The kit of claim 77, wherein said first primer is labeled with a second detectable label.

79. The kit of claim 78, wherein said first and said second detectable labels generate a signal for identifying a nucleotide at a given position of said template DNA molecule.

80. The kit of claim 78, wherein said first or second detectable label is one selected from the group consisting of:

a fluorescent label, an isotope, a chemiluminescent label, a quantum dot label, an antigen, and an affinity moiety.

81. The kit of claim 80, wherein said detectable label is a rhodamine label or a cyanine label.

82. A DNA polymerase produced by expressing a polynucleotide encoding a DNA polymerase, wherein said DNA polymerase comprises the sequence of SEQ ID NO:

2 except a mutation at P410 and A485.

84. The DNA polymerase of claim 82 or 83, wherein said mutation at position P410 is a P410L mutation.

85. The DNA polymerase of claim 82 or 83, wherein said mutation at position A485 is an A485T mutation.

86. The DNA polymerase of claim 82 or 83, wherein said mutation at position P410 is a P410L mutation and said mutation at position A485 is a A485T mutation.

83. A DNA polymerase produced by the steps:

(a) introducing a mutation into a polynucleotide encoding a wild-type DNA polymerase comprising the sequence of SEQ ID NO;

2 to produce a mutant polynucleotide encoding a mutant DNA polymerase comprising the sequence of SEQ ID NO;

2 except mutations at positions P410 and A485; and

(b) expressing said mutant polynucleotide to produce said mutant DNA polymerase.

87. A DNA polymerase produced by expressing a polynucleotide encoding a mutant DNA polymerase, wherein said mutant DNA polymerase comprises the sequence of SEQ ID NO:

2 except one or more mutations at D141, E143, P410, and A485.

88. The DNA polymerase of claim 87, wherein said one or more mutations at D141 and E143 are D141A and E143A.

89. A composition comprising a DNA polymerase produced by expressing in said composition a polynucleotide encoding a DNA polymerase comprising the sequence of SEQ ID NO:

2 except mutations at P410 and A485 and optionally D141 and E143.

91. The composition of claim 89 or 90, wherein said mutation at P410 is a P410L mutation.

92. The composition of claim 89 or 90, wherein said mutation at A485 is an A485T mutation.

93. The composition of claim 89 or 90, wherein said mutation at P410 is a P410L mutation and said mutation at A485 is an A485T mutation.

94. The composition of claim 93, wherein said mutation at D141 is a D141A mutation and said mutation at E143 is a E143A mutation.

90. A composition comprising a DNA polymerase produced by the steps:

(a) introducing a mutation into a polynucleotide encoding a wild-type DNA polymerase to produce a mutant polynucleotide encoding a mutant DNA polymerase comprising the sequence of SEQ ID NO;

2 except mutations at P410 and A485 and optionally D141 and E143; and

(b) expressing said mutant polynucleotide to produce said composition comprising said mutant DNA polymerase.